logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Stocks > HK Stock

GEELY AUTO (00175) on April 29 spent HK$37.8916 million to repurchase 1.694 million shares.

date
16:44 29/04/2026
avatar
GMT Eight
Geely Automobile (00175) announced that on April 29, 2026, it spent HKD 37.8916 million to repurchase 1.694 million shares.
Geely Auto (00175) announced on April 29, 2026 that it will spend HK$37,891.6 million to repurchase 169.4 million shares.
Related Articles
HK Stock
STERLING GP (01825) has appointed Zhang Yuan as an Independent Non-Executive Director.
HK Stock
JINGCHENG MAC (00187) released its first-quarter financial results, with a net loss attributable to shareholders of approximately 32.21 million yuan, an increase of about 1.7 times year-on-year.
HK Stock
HUTCHMED (00013): Sovleplenib, a Chinese new drug used to treat warm antibody type autoimmune hemolytic anemia patients, has received acceptance for market application and has been included in priority review and breakthrough therapy varieties.
STERLING GP (01825) has appointed Zhang Yuan as an Independent Non-Executive Director.
HK Stock
JINGCHENG MAC (00187) released its first-quarter financial results, with a net loss attributable to shareholders of approximately 32.21 million yuan, an increase of about 1.7 times year-on-year.
HK Stock
HUTCHMED (00013): Sovleplenib, a Chinese new drug used to treat warm antibody type autoimmune hemolytic anemia patients, has received acceptance for market application and has been included in priority review and breakthrough therapy varieties.
HK Stock
RECOMMEND
China Leads as Humanoid Robotics Reach Commercial Turning Point
China Leads as Humanoid Robotics Reach Commercial Turning Point
icon
29/04/2026
AI Disruption Reshapes US Equity Valuations as Terminal Value Volatility Takes Center Stage
AI Disruption Reshapes US Equity Valuations as Terminal Value Volatility Takes Center Stage
icon
29/04/2026
Political Bureau Meeting Sets Tone for Growth Eight Key Takeaways on Property Capital Markets and Monetary Policy
Political Bureau Meeting Sets Tone for Growth Eight Key Takeaways on Property Capital Markets and Monetary Policy
icon
29/04/2026
logo
Contact US
qr
+852 - 60190728
gmteight@futurecultural.com
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2026 GMT EIGHT Holdings. All Rights Reserved.